Curated News
By: NewsRamp Editorial Staff
June 23, 2025
Nutriband's AVERSA Fentanyl Patch Hits Key Milestone, $15 Price Target Set
TLDR
- Nutriband's AVERSA Fentanyl patch development and $15 price target offer investors a strategic advantage in the biotech sector with projected FY2027 EPS of $1.57.
- Nutriband completes commercial manufacturing for AVERSA Fentanyl, proceeding with a Phase 1 trial under the 505(b)(2) pathway, aiming for NDA submission by late 2025.
- AVERSA technology by Nutriband aims to reduce drug abuse, making a significant impact on public health by preventing misuse of transdermal patches with abuse potential.
- Discover how Nutriband's innovative AVERSA technology is setting new standards in abuse-deterrent transdermal patches, with a Phase 1 trial on the horizon.
Impact - Why it Matters
The development of Nutriband's AVERSA Fentanyl patch is a critical step forward in addressing the opioid crisis by introducing an abuse-deterrent technology that could significantly reduce the potential for misuse and accidental exposure. This innovation not only has the potential to save lives but also positions Nutriband as a leader in the pharmaceutical industry's fight against drug abuse. The financial and regulatory progress highlighted in the report underscores the viability and importance of this technology, making it a noteworthy development for investors, healthcare professionals, and the general public alike.
Summary
Nutriband Inc. (NASDAQ: NTRB), in collaboration with Kindeva, has achieved a significant milestone with the successful completion of commercial manufacturing and scale-up for its AVERSA Fentanyl, an abuse-deterrent transdermal patch. This achievement has prompted Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, to set a new $15 price target for Nutriband, highlighting the company's progress towards initiating clinical supplies production and submitting an Investigational New Drug (IND) application for a Phase 1 trial. The AVERSA program, following the 505(b)(2) regulatory pathway, is seen as a low-risk venture with the potential to significantly impact the fight against drug abuse. LeBoyer has also revised his FY2027 EPS forecast upwards to $1.57, anticipating full-year sales to commence in FY2027 following an NDA submission expected between late 2025 and early 2026. For more details, the full report is available here.
Nutriband's AVERSA technology represents a groundbreaking approach to preventing the abuse, misuse, and accidental exposure of drugs with abuse potential, marking a pivotal advancement in transdermal pharmaceutical products. The company's innovative efforts are further supported by BioMedWire, a specialized communications platform that amplifies news and updates in the Biotechnology and Life Sciences sectors, ensuring widespread recognition and awareness. For investors and stakeholders seeking the latest updates on Nutriband, additional information can be found at https://ibn.fm/NTRB.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband's AVERSA Fentanyl Patch Hits Key Milestone, $15 Price Target Set
